Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Neoplasms 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

pegaspargase 14Etoposide 11Dexamethasone 11Gemcitabine 10spartalizumab 6Oxaliplatin 4sintilimab 3Radiotherapy 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Methotrexate 3Asparaginase 3tislelizumab 2camrelizumab 2Lenalidomide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2Busulfan 2Azacitidine 2toripalimab 1tofacitinib 1ruxolitinib 1romidepsin 1pembrolizumab 1fludarabine phosphate 1avelumab 1apatinib 1Thalidomide 1Sensitivity and Specificity 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Extranodal NK-T-Cell × Basiliximab × Clear all
NCT04337593 2020-04-07

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

Beijing Tongren Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡